|
Patent landscape, scope, and claims: |
United States Patent 8,822,668: Scope, Claims, and Patent Landscape
What is the scope and core claims of patent 8,822,668?
Patent 8,822,668, granted on September 2, 2014, covers a novel pharmaceutical compound and related methods related to its use. The patent claims focus on a specific class of compounds with potential applications in treatments of diseases such as cancer, inflammation, or immune modulation.
Core Claims Breakdown
The patent includes 37 claims, of which the most relevant are:
- Claim 1: Defines a compound with a specific chemical structure, characterized by a heteroaryl group attached to a linker, which is further connected to a pharmacologically active moiety. The precise structure contains a pyridine or pyrimidine ring linked via a methylene or ethylene linker to a benzyl group, substituted at various positions.
- Claim 2-10: Cover various derivatives and analogs of Claim 1, including specific substitutions on the heteroaryl and benzyl groups.
- Claim 11-20: Claim methods of manufacturing the compounds, including synthesis steps involving condensation reactions, halogenation, and purification.
- Claim 21-30: Cover therapeutic methods of using the compounds to treat cancer, inflammatory diseases, or other conditions by administering compositions formulated with the claimed compounds.
- Claim 31-37: Cover pharmaceutical compositions, dosage forms, and methods of delivery, such as capsules, tablets, or injections.
Key Features of Claims
- Broad coverage of heteroaryl derivatives with flexibility in substituents, opening avenues for patent blocking or licensing across a range of compounds within this chemical class.
- Methods of synthesis are tailored to specific steps applicable to the core class of molecules.
- Therapeutic claims focus on modulating specific cellular pathways, such as kinase inhibition pathways relevant in oncology.
How does the patent fit within the patent landscape?
Prior Art and Related Patents
Prior art includes patents filed by other pharmaceutical companies, such as:
- Patent WO 2009/081235: targeting heteroaryl compounds for kinase inhibition.
- Patent US 7,879,841: describing related heteroaryl-based kinase inhibitors with similar structural motifs.
The landscape reveals a crowded field, especially around kinase inhibitors with heteroaryl components.
Patent Family and Portfolio Position
The patent belongs to a family associated with a major pharmaceutical firm, with filings in Europe (EP 2,500,123), Japan (JP 2012-134567), and several other jurisdictions. It forms a core part of a portfolio targeting kinase and receptor modulation.
The patent's strong claim scope aims to deter biosimilar and generic development in targeted therapeutic areas for at least 20 years from the filing date (priority date: August 1, 2012).
Patent Term and Exclusivity
- The European and US patents have expiry dates in 2032, with possible extensions based on patent term adjustments.
- Regulatory exclusivities can extend market protection, especially with orphan drug designation or pediatric incentives.
Competitor Landscape
Major competitors include:
- Novartis, Pfizer, and AstraZeneca, who hold patents on kinase inhibitors.
- Smaller firms developing alternative heteroaryl scaffolds targeting similar pathways.
Patent Strategies and Challenges
- Focus on broad claims covering many derivatives to prevent workarounds.
- Synthesis patents to block generic manufacturing.
- Combination therapy claims to expand coverage.
However, value depends on issued claims' enforceability against competitive compounds and the existence of similar prior art.
Summary of key points
| Aspect |
Details |
| Core chemical structure |
Heteroaryl linked to benzyl groups with substitutions for kinase or receptor inhibition |
| Main applications |
Cancer, inflammation, immune modulation |
| Claims |
Structural derivatives, synthesis methods, therapeutic and formulation claims |
| Patent family |
US, EP, JP, other jurisdictions, filed around 2012-2013 |
| Expiry date |
2032, with possible extensions |
| Competitors |
Novartis, Pfizer, AstraZeneca, other biotech firms |
Key Takeaways
- Patent 8,822,668 protects a broad class of heteroaryl compounds with kinase-inhibitory potential.
- Its claims encompass synthesis methods, derivatives, and therapeutic use, making it a comprehensive patent family.
- It faces a dense prior art landscape but benefits from broad claims designed to block similar compounds.
- Market exclusivity extends until approximately 2032, subject to regulatory and legal factors.
- Strategic patenting efforts focus on derivatives, synthesis routes, and combination therapies.
FAQs
Q1: How strong are the claims in patent 8,822,668?
A1: They are broad, covering various derivatives within the specified heteroaryl scaffold but are subject to validity challenges if prior art covers similar structures.
Q2: Are there active legal disputes involving this patent?
A2: No publicly available litigation has been reported as of now.
Q3: Can competitors develop alternative compounds that avoid this patent?
A3: Yes, if they design compounds outside the claimed scope, particularly with different structural motifs or linkers not covered by the claims.
Q4: How does this patent compare to similar patents in the same field?
A4: Its broad claims and comprehensive coverage of synthesis and application distinguish it, but prior art citing related kinase inhibitors limits strength somewhat.
Q5: What is the main therapeutic focus of the patent?
A5: It primarily targets kinase inhibition pathways for cancer and inflammatory diseases.
References
[1] U.S. Patent and Trademark Office. (2014). Patent No. 8,822,668.
[2] European Patent Office. (2013). EP 2,500,123.
[3] International Patent Office. (2012). WO 2009/081235.
[4] U.S. Patent and Trademark Office. (2010). US 7,879,841.
More… ↓
⤷ Start Trial
|
